CD79A and infection: When IgG and IgA antibodies against SARS-CoV-2 were analyzed prior to the first vaccine dose, five (12.5%) and nine (22.5%) patients had IgG and IgA antibodies against SARS-CoV-2, respectively (subjects with a previous natural infection).